Ziritaxestat

SKU: orb1303261

Description

Ziritaxestat (GLPG1690) is a small molecule autotaxin inhibitor. It has been investigated in a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). Preclinical studies in vitro and in animal models have demonstrated its role in targeting the LPA pathway relevant to fibrotic diseases.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1628260-79-6
• MW: 588.7
• Purity: 97.00% (May vary between batches)
• Formula: C₃₀H₃₃FN₈O₂S
• SMILES: CCc1nc2c(C)cc(cn2c1CNc1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1
• Target: PDE
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.4 mM);DMSO:50 mg/mL (84.93 mM);H2O:< 0.1 mg/mL (insoluble)

Bioactivity

• Target IC50:
  ATX:131 nM

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

autotaxin, Inhibitor, GLPG1690, GLPG-1690, GLPG 1690, inhibit, Ziritaxestat, Phosphodiesterase (PDE), phosphodiesterase

Compound Identifiers

PubChem CID

137699073